4Straumann E, Bertel O. Acute coronary syndrome and myocardial infarctnew definitions[J]. Ther Umsch .2002, 59(2) :66 - 71.
5Bayes - Genis A, Mateo J, Santalo M, et al. D - Dimer is an early diagnostic marker of coronary, ischemia in patients with chest pain[J]. Am Heart J,2000, 140(3) :379 - 384.
6Quilici j, Gallo R. Physiopathology of acute coronary syndromes [J].Ann Cardiol Angeiol, 1999.48(9- 10):611-623.
7Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin - like growth factor(IGF) dependent IGF binding protein - 4 protease secreted by human fibroblasts is pregnancy - associated plasma protein - A[J]. Proc Natl Acad Sci USA, 1999, 96(5) :3149-3153.
8Fialova L, Malbohan IM. Pregnancy - associated plasma protein A:theoretical and clinical aspects[J]. Bratisl Lek Listy, 2002,103(6) : 194- 205.
9Bersinger NA, Noble P, Nicolaides KH. First- trimester maternal serum PAPP-A, SPI and M - CSF levels in normal and trisomic twin pregnancies[J]. Prenat Diagn,2003 ,??.3(2) : 157 - 162.
10Wapner R, Thom E, Simpson JL, et al . First trimester maternal serum biochemistry and fetal nuchal translucency, screening (BUN) study group.First- trimester screening for trisomies 21 and 18[J]. N Engt J Med,2003, 349(15) : 1405 - 1413.
2[1]David A, Krantz B. S John W, et al. First trimester down syndrome screening:Free β-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am I Obstel Gynecol, 1996,174:612-616.
3[2]Westergaard JG, Teisner B, Hau J, et al. Placental protein measurements in complication pregnancies: Pregnancy-related hypertensin. Br J Obstet Gynecol, 1984,91:1216-1224.
4[5]Brambati B, Macintosh MCM, Teisncr B, et al. Low maternal serum levels of pregnancy associated plasma protein A in the first trimesters in association with abnormal fetal karyotype. Br J Obstet Gynecol, 1993,100(4) :324-326.
5[7]Zimmermann R, Hucha A, Savdoelli G, et al. Serum parameters and nuchal translucency in first trimester screeing for fetal chromosomol abnormalities.Br J Obstet Gynecol, 1996,103:1009-1014.
6Cheng G C，Circulation，1993年，87卷，1179页
7Peter D. Brown.Matrix metalloproteinase inhibitors[J].Breast Cancer Research and Treatment (-).1998(1-3)
8StephensNG,ParsonsA,SchofieldPM ,etal. The Lancet . 1 996
6Alhadi HA, Fox KA. Do we need additional markers of myocytenecrosis : the potential value of heart fatty-acid-binding protein [ J].Q J Med, 2004, 97 (4) : 187-198.
7Chan CP, Sanderson JE, Glatz JF, et al. A superior earlymyocardial infarction marker: Human heart-type fatty acid-bindingprotein [J]. Z Kardiol, 2004,93 (5) : 388-397.
8Dimitris T, Anna-Maria K, Elli S, et al. New biochemical markersin acute coronary syndromes [ J ]. Cur Med Chem, 2008, 15(13): 1288-1296.
9Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses ofacute cardiac ischemia in the emergency department [ J]. N Engl JMed, 2000, 342 (16) : 1163-1170.
10Marc PB, David AM. Defining a role for novel biomarkers in acutecoronary syndromes [J]. Clin Chem, 2008,54 (9) : 1424-1431.
